首页> 外文期刊>Journal of Clinical Microbiology >FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance
【24h】

FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance

机译:FIND结核菌菌株库:研究人员和开发人员在进行检测结核分枝杆菌及其相关耐药性测试的资源

获取原文
           

摘要

The spread of multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR) TB hampers global efforts in the fight against tuberculosis. To enhance the development and evaluation of diagnostic tests quickly and efficiently, well-characterized strains and samples from drug-resistant tuberculosis patients are necessary. In this project, the Foundation for Innovative New Diagnostics (FIND) has focused on the collection, characterization, and storage of such well-characterized reference materials and making them available to researchers and developers. The collection is being conducted at multiple centers in Southeast Asia, South America, Eastern Europe, and soon the sub-Saharan Africa regions. Strains are characterized for their phenotypic resistances and MICs to first-line drugs (FLDs) and second-line drugs (SLDs) using the automated MGIT 960 system following validated procedures and WHO criteria. Analysis of resistance-associated mutations is done by whole-genome sequencing (WGS) using the Illumina NextSeq system. Mycobacterial interspersed repetitive-unit–variable-number tandem-repeat analysis and WGS are used to determine strain lineages. All strains are maintained frozen at ?80°C ± 10°C as distinct mother and daughter lots. All strains are extensively quality assured. The data presented here represent an analysis of the initial part of the collection. Currently, the bank contains 118 unique strains with extracted genomic DNA and matched sputum, serum, and plasma samples and will be expanded to a minimum of 1,000 unique strains over the next 3 years. Analysis of the current strains by phenotypic resistance testing shows 102 (86.4%), 10 (8.5%), and 6 (5.1%) MDR, XDR, and mono/poly resistant strains, respectively. Two of the strains are resistant to all 11 drugs that were phenotypically tested. WGS mutation analysis revealed FLD resistance-associated mutations in the rpoB, katG, inhA, embB, embA, and pncA genes; SLD resistance in the gyrA, gyrB, rrs, eis, and tlyA genes; and ethionamide resistance in the ethA genes. Most important lineages are represented in the bank, and further collections have been initiated to increase geographic and lineage diversity. The bank provides highly characterized and high-quality strains as a resource for researchers and developers in support of the development and evaluation of new diagnostics and drug resistance detection tools.
机译:耐多药结核(TB)和广泛耐药(XDR)结核的扩散阻碍了全球抗击结核病的努力。为了快速有效地促进诊断测试的开发和评估,必须从耐药结核病患者中获得特征明确的菌株和样品。在该项目中,创新诊断新基金会(FIND)致力于收集,表征和存储此类特征鲜明的参考材料,并提供给研究人员和开发人员。收集工作正在东南亚,南美,东欧以及不久的撒哈拉以南非洲地区的多个中心进行。使用经过验证的程序和WHO标准,使用自动化MGIT 960系统对菌株对一线药物(FLD)和二线药物(SLD)的表型抗性和MIC进行表征。使用Illumina NextSeq系统通过全基因组测序(WGS)对耐药相关突变进行分析。分枝杆菌散布的重复单位-可变数目串联重复分析和WGS用于确定菌株谱系。作为母子,所有菌株均保持在80°C±10°C下冷冻。所有菌株均得到广泛的质量保证。此处提供的数据代表对集合初始部分的分析。目前,该库包含118种独特菌株,并带有提取的基因组DNA以及匹配的痰液,血清和血浆样品,并将在未来3年内扩展到​​至少1000种独特菌株。通过表型抗性测试对当前菌株进行的分析分别显示了102(86.4%),10(8.5%)和6(5.1%)的MDR,XDR和单/多抗性菌株。其中两个菌株对所有11种经过表型测试的药物均具有抗药性。 WGS突变分析揭示了 rpoB katG inhA embB 中FLD抗性相关突变embA pncA 基因; gyrA gyrB rrs eis tlyA 基因中的SLD抗性;和 ethA 基因中的乙硫酰胺抗性。最重要的宗族在银行中有代表,并且已经开始进行进一步的收集以增加地理和宗族的多样性。该银行为研究人员和开发人员提供了具有高特征和高质量的菌株,以支持开发和评估新的诊断方法和耐药性检测工具。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号